Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-07220060, Atirmociclib
PF-07220060 CDK4 inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | PF-07220060 to be taken by mouth as a tablet in combination with fulvestrant (a solution for injection) |
| Arm B | ACTIVE_COMPARATOR | Investigator's choice of therapy of either: * Fulvestrant alone (a solution for injection), or * Everolimus in combination with exemestane, both a tablet to be taken by mouth. |
| Name | Type | Description |
|---|---|---|
| PF-07220060 CDK4 inhibitor | DRUG | Experimental |
| Fulvestrant | DRUG | Experimental and Active comparator |
| Everolimus | DRUG | Active Comparator |
| Exemestane | DRUG | Active Comparator |
Inclusion Criteria: * Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent. * Documented estrogen receptor (ER) and/or progesterone receptor (PR)- positive tumor * Do...
Top 20 of 92 competitors
Atirmociclib is an investigational small molecule being studied for use in advanced or metastatic breast cancer, liposarcoma, prostate cancer, and adenocarcinoma of the lung. It is also being evaluated in healthy participants for drug interaction studies. Atirmociclib is not yet approved and remains in clinical development.
Atirmociclib is a CDK inhibitor, belonging to the -ciclib class of drugs that target cyclin-dependent kinases. It is being studied for its potential role in treating certain cancers by interfering with cell cycle progression.
Atirmociclib is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
Atirmociclib is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Clinical trials are ongoing to assess its safety, tolerability, and potential efficacy in various cancer types.
Atirmociclib is being studied in several clinical trials, including NCT04557449 in advanced solid tumors, NCT06465368 in postmenopausal breast cancer, NCT06760637 in HR-positive HER2-negative breast cancer, and NCT06897683 in healthy adults. These trials are at various stages and are conducted internationally.
Yes, Atirmociclib is also known as PF-07220060. The drug is referred to by this alternative name in clinical trial registries and scientific literature. It is also sometimes listed with combination partners such as PF-07104091 in certain study contexts.